SCHEMBL5161725

SCHEMBL5161725

COc1ccc(OC(F)C(F)F)cc1C=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB1 Q9H4B7 1/20 0.49
ALDH1A1 P00352 3/20 0.47
JUN P05412 1/20 0.45
NFKB1 P19838 1/20 0.45
KDM4E B2RXH2 2/20 0.44
TSHR P16473 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
RAB9A P51151 1/20 0.43
ERN1 O75460 4/20 0.42
ABCG2 Q9UNQ0 1/20 0.42
NFE2L2 Q16236 2/20 0.41
CYP1A1 P04798 2/20 0.41
CYP1B1 Q16678 2/20 0.41
CYP1A2 P05177 1/20 0.41
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
TRIM24 O15164 1/20 0.39
TYR P14679 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7414736 0.87 TUBB1 (0.51) TUBB1ALDH1A1JUNNFKB1KDM4E
SCHEMBL29392394 0.79 ALDH1A1 (0.71) TUBB1ALDH1A1JUNNFKB1KDM4E
SCHEMBL172939 0.79 ALDH1A1 (0.71) TUBB1ALDH1A1JUNNFKB1KDM4E
SCHEMBL4680098 0.76 ALDH1A1 (0.53) TUBB1ALDH1A1JUNNFKB1KDM4E
SCHEMBL29125481 0.76 ERN1 (0.41) ALDH1A1KDM4EERN1
SCHEMBL18885196 0.75 TUBB1 (0.55) TUBB1ALDH1A1JUNNFKB1KDM4E
SCHEMBL29432755 0.74 ERN1 (0.56) TUBB1ALDH1A1KDM4ETSHRTDP1
SCHEMBL273404 0.74 ERN1 (0.56) TUBB1ALDH1A1KDM4ETSHRTDP1
SCHEMBL1985337 0.74 TUBB1 (0.51) TUBB1ALDH1A1JUNNFKB1KDM4E
SCHEMBL4599003 0.73 TUBB1 (0.54) TUBB1ALDH1A1JUNNFKB1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7241798-B2 NK1 antagonists PFIZER INC. (US) 2007-07-10 US disclosed
EP-1756056-A1 AZA-BICYCLO[3.1.0]HEX-1-YL DERIVATIVES ACTIVE AS NK1 ANTAGONISTS Pfizer Products Inc. (US) 2007-02-28 EP disclosed
WO-2005121085-A1 AZA-BICYCLO`3.1.0!HEX-1-YL DERIVATIVES ACTIVE AS NK1 ANTAGONISTS PFIZER PRODUCTS INC. (US) 2005-12-22 WO disclosed
US-20050272800-A1 NK1 antagonists PFIZER INC 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272800-A1 NK1 antagonists TACR1, TACR2, TAC3 TUBB1 2253/4885ALDH1A1 2620/4885JUN 1515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.